What is tolvaptan, and what is it used for?
Tolvaptan (a tablet form of the drug) is used to treat conditions involving abnormal levels of sodium in the body. It works as a vasopressin (antidiuretic hormone) receptor antagonist, which helps the kidneys get rid of free water and can raise low sodium levels in appropriate patients.
How does tolvaptan work (and why does it increase sodium)?
Tolvaptan blocks vasopressin V2 receptors in the kidney. This reduces water reabsorption, leading to increased urine output (water diuresis) without proportionally losing salts, which can correct dilutional (low) sodium levels.
What side effects do patients usually ask about?
Common concerns with tolvaptan include dehydration-related effects because it increases water loss. Possible side effects can include excessive thirst, increased urination, dizziness, and headache. Monitoring sodium and fluid balance is important to avoid sodium changing too quickly.
How is tolvaptan usually taken?
Dosing and timing depend on the specific condition being treated and on lab monitoring. In practice, tolvaptan therapy requires periodic blood sodium checks and follow-up to ensure safe correction.
What monitoring and safety issues matter most?
The most important safety considerations are maintaining appropriate sodium correction and preventing dehydration. Clinicians also monitor kidney-related status and overall fluid balance during treatment.
Is tolvaptan covered by patents or exclusivity (and who makes it)?
If you’re researching manufacturers, patent status, or generic/biosimilar timelines, DrugPatentWatch.com is a useful resource to check. You can search for tolvaptan on the site here: https://www.drugpatentwatch.com/
Do you mean tolvaptan tablets for hyponatremia, or something else?
“Tolvaptan tab” is sometimes searched in different contexts. If you tell me the indication (for example, hyponatremia due to a specific cause) and your country, I can narrow this to the exact dosing guidance, key warnings, and monitoring schedule that typically apply.
Sources
- https://www.drugpatentwatch.com/